GSK cancer drug Jemperli has been granted priority review by the U.S. Food and Drug Administration (FDA) after a pivotal trial showed no detectable signs of rectal tumors for at least one year in a significant proportion of patients. The move signals a potentially historic shift in how certain rectal cancers are treated.
If approved, the drug could allow selected patients to avoid chemotherapy, radiation and surgery, reshaping first‑line care for a disease long defined by invasive treatment. The FDA set a February 2027 decision deadline, but the application also qualifies for accelerated consideration under the National Priority Voucher program, meaning an earlier ruling is possible. The submission is also being reviewed through Project Orbis, which opens the door to coordinated international approvals.
The FDA’s review is based on AZUR‑1, a global phase II trial evaluating Jemperli as a standalone treatment for previously untreated stage II/III dMMR/MSI‑H locally advanced rectal cancer. The study met its primary endpoint by demonstrating clinical complete responses lasting at least 12 months. Interim safety findings were consistent with the drug’s established profile.
For decades, treatment for this subtype of rectal cancer has followed a rigid sequence: chemotherapy, radiation and surgery. While curative for many, the regimen often leaves patients with permanent, life‑altering complications. Abdullah said the current standard, while often effective, comes with a steep personal cost for many patients.
He pointed to the long‑term burdens patients routinely face after chemoradiation and surgery. Patients may also “experience issues with fertility, which is lost during chemo‑radiation,” along with “other debilitating treatment‑related side effects related to bowel, urinary, sexual, and body‑image consequences, which can take a major toll on day‑to‑day lives.” If Jemperli becomes a first‑line option, Abdullah said, these outcomes could be avoided for selected patients. The AZUR‑1 results build on earlier work from Memorial Sloan Kettering Cancer Center, which first demonstrated that PD‑1 blockade could produce complete responses without chemoradiation.
That is why identifying dMMR/MSI‑H through biomarker testing can be so important…although it does not guarantee that every patient will respond.” The FDA has set a February 2027 PDUFA date, but the application’s eligibility for the National Priority Voucher program could mean a decision comes earlier. GSK is also pursuing approval through Project Orbis, enabling simultaneous review by international regulators. Abdullah said the National Priority Voucher “provides for an expedited review process, so FDA action could occur ahead of that date,” though he declined to speculate beyond the agency’s stated timelines.
Extract — continue reading at the source.
